(MedPage Today) -- The FDA approved trastuzumab deruxtecan (T-DXd; Enhertu) in combination with pertuzumab (Perjeta) for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer.
(MedPage Today) -- At the San Antonio Breast Cancer Symposium, investigators from an international consortium reported that knowledge of BRCA1/2 mutation status strongly influenced surgical decision-making in young patients with stages I…
(MedPage Today) -- At the San Antonio Breast Cancer Symposium, researchers reported that real-time monitoring with smart pill bottles significantly improved adherence to adjuvant endocrine therapy compared with standard-of-care monitoring.
Greenwich LifeSciences Inc. (NASDAQ:GLSI) stock is trading higher on Monday, with a session volume of 2.804 million compared to the average volume of 81.85 thousand, as per data from Benzinga Pro.
Broadcast Retirement Network's Jeffrey Snyder discusses reducing the mortality of breast cancer with Steven Narod, MD, FRCPC, FRSC, Tier I Canada Research Chair in Breast Cancer, University of Toronto. Jeffrey Snyder, Broadcast Retirement…
Scientists have uncovered a powerful new antibody that disrupts a key protein helping triple-negative breast cancer survive and evade immunity. Triple-negative breast cancer (TNBC) is considered one of the most aggressive and difficult…
(MedPage Today) -- SAN ANTONIO -- Menopausal hormone therapy (MHT) did not increase breast cancer risk in women with BRCA mutations, according to a study reported here.
A prospective, multicenter cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) has validated an improved method for predicting treatment benefits in patients with hormone receptor-positive (HR+) metastatic breast…